Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Response to Kårhus et al. Regarding "<i>Ruminococcus gnavus</i> and Biofilm Markers in Feces From Primary Bile Acid Diarrhea Patients Indicate New Disease Mechanisms and Potential for Diagnostic Testing".

Gastro hep advances·2026
Same author

<i>Ruminococcus gnavus</i> and Biofilm Markers in Feces From Primary Bile Acid Diarrhea Patients Indicate New Disease Mechanisms and Potential for Diagnostic Testing.

Gastro hep advances·2025
Same author

DNA reference reagents isolate biases in microbiome profiling: a global multi-lab study.

mSystems·2025
Same author

Changing Gastrointestinal Transit Time Alters Microbiome Composition and Bile Acid Metabolism: A Cross-Over Study in Healthy Volunteers.

Neurogastroenterology and motility·2025
Same author

<i>Salmonella</i> Typhi Vi capsule prime-boost vaccination induces convergent and functional antibody responses.

Science immunology·2021
Same author

Exploring how microbiome signatures change across inflammatory bowel disease conditions and disease locations.

Scientific reports·2021

Related Experiment Video

Updated: Jul 10, 2026

Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus (MRSA) Infection
07:32

Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus (MRSA) Infection

Published on: September 1, 2023

New adjuvants: EU regulatory developments.

Dorothea Sesardic1, Sjoerd Rijpkema, Brijesh Prakash Patel

  • 1National Institute for Biological Standards and Control, Division of Bacteriology, Blanche Lane, South Mimms, Potters Bar, Hertfordshire, EN6 3QG, UK. dsesardic@nibsc.ac.uk

Expert Review of Vaccines
|October 13, 2007
PubMed
Summary

This paper reviews European Union (EU) regulations for introducing new vaccine adjuvants. It highlights safety requirements and bottlenecks slowing the approval process for these essential vaccine components.

More Related Videos

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
09:03

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development

Published on: June 19, 2018

Cationic Nanoemulsion-Encapsulated Retinoic Acid as an Adjuvant to Promote OVA&#45;Specific Systemic and Mucosal Responses
06:02

Cationic Nanoemulsion-Encapsulated Retinoic Acid as an Adjuvant to Promote OVA-Specific Systemic and Mucosal Responses

Published on: February 23, 2024

Related Experiment Videos

Last Updated: Jul 10, 2026

Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus (MRSA) Infection
07:32

Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus (MRSA) Infection

Published on: September 1, 2023

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
09:03

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development

Published on: June 19, 2018

Cationic Nanoemulsion-Encapsulated Retinoic Acid as an Adjuvant to Promote OVA&#45;Specific Systemic and Mucosal Responses
06:02

Cationic Nanoemulsion-Encapsulated Retinoic Acid as an Adjuvant to Promote OVA-Specific Systemic and Mucosal Responses

Published on: February 23, 2024

Area of Science:

  • Vaccinology
  • Regulatory Science
  • Pharmaceutical Development

Background:

  • Adjuvants are critical for enhancing vaccine immunogenicity and efficacy.
  • The European Union (EU) has specific regulatory frameworks for vaccine components.
  • Navigating these regulations is complex for novel adjuvant development.

Purpose of the Study:

  • To delineate EU regulatory requirements for new human vaccine adjuvants.
  • To identify key regulatory expectations across developmental, manufacturing, and final product stages.
  • To highlight challenges and bottlenecks impacting adjuvant approval timelines.

Main Methods:

  • Review of European Union (EU) regulatory documents and guidelines.
  • Analysis of safety expectations for adjuvants during preclinical and clinical development.
  • Identification of common regulatory concerns and process inefficiencies.

Main Results:

  • Comprehensive overview of EU regulatory expectations for adjuvants at various stages.
  • Emphasis on stringent safety assessments in preclinical and clinical trials.
  • Identification of specific bottlenecks contributing to delayed approvals.

Conclusions:

  • Streamlining EU regulatory pathways is crucial for timely adjuvant introduction.
  • Addressing identified bottlenecks can accelerate the availability of innovative vaccine adjuvants.
  • Clearer regulatory guidance can foster advancements in vaccine technology.